Swiss National Bank Has $10.07 Million Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Swiss National Bank lessened its stake in shares of Bausch Health Companies Inc. (NYSE:BHCGet Rating) by 11.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,207,260 shares of the company’s stock after selling 149,600 shares during the quarter. Swiss National Bank’s holdings in Bausch Health Companies were worth $10,073,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BHC. WASHINGTON TRUST Co acquired a new stake in shares of Bausch Health Companies in the first quarter worth $28,000. First Horizon Advisors Inc. grew its stake in shares of Bausch Health Companies by 85.1% in the second quarter. First Horizon Advisors Inc. now owns 5,607 shares of the company’s stock worth $45,000 after acquiring an additional 2,578 shares during the last quarter. Assetmark Inc. grew its stake in shares of Bausch Health Companies by 454.3% in the second quarter. Assetmark Inc. now owns 10,421 shares of the company’s stock worth $87,000 after acquiring an additional 8,541 shares during the last quarter. XR Securities LLC acquired a new stake in shares of Bausch Health Companies in the second quarter worth $91,000. Finally, Range Financial Group LLC grew its stake in shares of Bausch Health Companies by 11.5% in the second quarter. Range Financial Group LLC now owns 12,013 shares of the company’s stock worth $100,000 after acquiring an additional 1,237 shares during the last quarter. Institutional investors and hedge funds own 70.07% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Bausch Health Companies in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Royal Bank of Canada raised their target price on Bausch Health Companies from $4.50 to $8.00 and gave the stock a “sector perform” rating in a research report on Thursday, September 1st. Piper Sandler reduced their target price on Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Friday, September 9th. Truist Financial cut Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Finally, JPMorgan Chase & Co. cut Bausch Health Companies from an “overweight” rating to a “neutral” rating in a research report on Thursday, July 28th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.60.

Bausch Health Companies Stock Up 0.1 %

Shares of NYSE BHC opened at $7.57 on Monday. The stock has a market cap of $2.74 billion, a PE ratio of 10.81, a PEG ratio of 0.13 and a beta of 0.99. The business has a fifty day moving average of $7.03 and a two-hundred day moving average of $7.67. Bausch Health Companies Inc. has a 52-week low of $4.00 and a 52-week high of $28.35. The company has a debt-to-equity ratio of 48.05, a quick ratio of 0.77 and a current ratio of 1.05.

About Bausch Health Companies

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Further Reading

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHCGet Rating).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.